Navigation Links
Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Date:2/28/2008

- Studies planned on the genetics of; - Asian populations with regard to risk associated in the development of

osteoporosis or cardiovascular disease - North American populations with regard to athletic/exercise performance

in response to nutritional products (nutrigenomics) - North American populations with regard to skin appearance (dermagenomics)

WALTHAM, Mass., Feb. 28 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) reported today that it has executed a new research agreement with Access Business Group International LLC (ABG), a subsidiary of Alticor Inc. The research agreement encompasses four main areas; osteoporosis, cardiovascular disease, nutrigenomics, and dermagenomics. Interleukin Genetics will be conducting various clinical studies, which shall be fully funded by Alticor. Studies will look to correlate single nucleotide polymorphic (SNPs) gene variations to the risk of osteoporosis or cardiovascular disease in Asian populations. Other studies will seek to identify genetic factors that influence athletic performance and skin appearance (wrinkles, elasticity, aging) for the purpose of developing products to enhance healthy aging.

Under the terms of the agreement, ABG will pay Interleukin Genetics $1.2 million during 2008 for the research. Approximately $800,000 of unspent funding from prior research agreements with Alticor shall also be credited against the costs incurred under this new agreement.

"This is our eighth research agreement with Alticor and we are pleased to continue to work with our partner on the development of genetic risk assessment tests in the field of osteoporosis and cardiovascular disease in new populations as well as
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
2. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
3. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
4. Interleukin Genetics Announces Management and Board Appointments
5. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
6. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
7. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
8. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
9. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...OOK, N.Y., Nov. 6 BioSpe...harmaceutical company developing first-in-class co...ncial results for the third quarter ended Septembe...in September of this year, the FDA,s Arthritis Adv... of 12-0, the approval of XIAFLEX(TM) for the trea...
(Date:11/6/2009)...IENNA, Austria, November 6 EUCODIS...nufacturing, and marketing enzymes for the,chemica...o a research,agreement with Bio Sidus, the leading..., The agreement gives EUCODIS Bioscience exclu...t - to Bio Sidus, proprietary collection of,psychr...
(Date:11/6/2009)...RY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Bio...the "Company") today announced updated results fro...atients with sarcomas metastatic to the lung in a ...Tissue Oncology Society Meeting held in Miami Beac...resentation, entitled "A Phase II Study of Intrave...
(Date:11/5/2009)...ORTATION -- Gone hybrid . . . , Fuel economy r... now posted at the www.fueleconomy.gov web site,... maintains for the U.S. Department of Energy and t...he top 10 vehicles on the best fuel economy list a...PG city; 48 highway). "This list proves that hybri...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3
...ent Response to Novel Beta Blocker ...dolol, an investigational,pharmacologically unique...reduces hospitalization and death among heart fail...ing to results of a large DNA study presented,toda...ailure Society of,America. Researchers found that ...
...US$10 million received based on the positive revie...ultiple sclerosis trial - EDMONTON, Sept. 22 /PRN..., a leading developer in the treatment of multiple...ved the US$10 million milestone payment from its,p...ment is based on the previously announced positive...
...l Systems and BrainLAB enabling, non-invasive tr...vous system, PALO...ctors around the globe are turning more and,more t... for the treatment,of cancer and other conditions.... Systems (NYSE: VAR ) and BrainLAB, doctors are p...
Other Biology Technology:Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 2Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 3Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 5
(Date:11/4/2009)...HILADELPHIA Although scientists are reluctant to ...n method, evidence continues to grow about its pro...published in Cancer Prevention Research , a journ..., which suggests some reduction in oral cancer. ,...f medicine in the Department of Thoracic/Head and ...
(Date:11/4/2009)...eavy traffic corridors in the cities of Long Beach...roportion of preventable childhood asthma, and the...n the disease has likely been underestimated, acco... California (USC). , The study, which appears i...blic Health , estimated that nine percent of all c...
(Date:11/4/2009)...ancouver, BC - Lowly bacteria, it turns out, hold ...turing plants around the world clean up toxic wast..., specifically RDX, were invented back in World Wa...decades. These high-energy compounds are often us...ful version of TNT. , But with increased knowl...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 1AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 3
...ug development : only "lucrative","markets" get ex...ve,seen very promising drugs candidates or related...de with it, even if millions would have,been saved...is to find,a drug candidate that affect a "profita...ne. PLoS Medecine has an article about a possible,...
...f the Chinese hybrid rice genome, which was publis...s have recently finished the fine map of the rice ...e of PLoS Biology (Vol.3 Issue 2, 2005), scientist...eported a "much improved, near-complete genome ana...sativa." , The fine maps of the rice genome seque...
...lar signaling mechanism whose existence has been,k...since the,identification of a mutant strain of Dro...Hunt Morgan’s lab in 1910. Later studies,revealed ...t extends,through both sides of the cell membrane ...partner, such as the protein Delta, presented,on t...
Other Biology News:Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Whole genome fine map of rice completed 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
Mae II from Roche Applied Science
...etase Activity Kit ADAM17 Activity Kit TNF-α...T FROM LIGHT. AVOID FREEZE/THAW CYCLES. The InnoZy...itive assay designed to measure human TACE activit...creening enzyme inhibitors. An Anti-Human TACE-Coa...
...garose Gel-Digesting Preparation contains a unique...ENTRE for simple, quantitative recovery of intact ...els following electrophoresis in TAE, TBE, MOPS, o...tly in the TAE, TBE, MOPS, and phosphate electroph...
Hot StarTaq Master Mix Kit from QIAGEN
Biology Products: